Platforms We Use
Observational Medical Outcomes Partnership
The Observational Medical Outcomes Partnership (OMOP) was a public-private partnership established to inform the appropriate use of observational healthcare databases for studying the effects of medical products.
Prognosis uses OMOP as the foundation for its Data Warehouse. The Prognosis Extended OMOP data model, OMOP-PX, provides a complete framework for health data, including healthcare, financial and claims data, genomics and patient outcomes.
Observational Health Data Sciences & Informatics
Observational Health Data Sciences & Informatics was established at Columbia University to support the use of the OMOP model. Members of the OHDSI community include pharmaceutical companies, hospital systems, and academic medical centers. The OHDSI community has created a number of open source products that run on the OMOP model, including Atlas, a sophisticated query tool, and Achilles, a data profiling tool.
i2b2 (Informatics for Integrating Biology and the Bedside) is an NIH-funded National Center for Biomedical Computing based at Partners HealthCare System. The i2b2 Center is developing a scalable informatics framework that will enable clinical researchers to use existing clinical data for discovery research and, when combined with IRB-approved genomic data, facilitate the design of targeted therapies for individual patients with diseases having genetic origins. This platform currently enjoys wide international adoption by the CTSA network, academic health centers, and industry. i2b2 is funded as a cooperative agreement with the National Institutes of Health.
tranSMART is an open source framework for knowledge management of translational research data including both molecular information such as DNA, RNA, and proteins along with clinical information such as clinical trial outcomes and patient demographics and disease conditions.
tranSMART was originally developed by Recombinant Data Corp for Johnson & Johnson’s Centocor division. The project used the i2b2 source code as a starting point for a genomic analysis platform that allowed researchers to comb through 150 previously completed clinical trials to use gene expression data to identify drugs with therapeutic value for individuals with specific genomic profiles.
In 2012, Johnson & Johnson released the software as an open source project under the GNU Public License, and the University of Michigan took a leadership role in forming a community of researchers, pharmaceutical companies and academic institutions to leverage the platform in new and innovative ways.
SHRINE, the Shared Health Research Information Network, is a software program that links i2b2 systems into a network that supports query of the entire network from any node in the network. SHRINE helps researchers overcome one of the greatest problems in population-based research: Compiling large groups of well-characterized patients.
Because counts are aggregate, patient privacy is protected.
Networks We Support
The ACT Network is a real-time platform allowing researchers to explore and validate feasibility for clinical studies across the NCATS Clinical and Translational Science Award (CTSA) consortium, from their desktops. ACT helps researchers design and complete clinical studies, and is secure, HIPAA-compliant and IRB-approved.
ACT was developed collaboratively by members of NCATS’ Clinical and Translational Science Award (CTSA) consortium, with funding from the NIH National Center for Advancing Translational Sciences.
ARCH (formerly SCILHS) engages patients and clinicians as collaborators with researchers, to prioritize research, design studies, and interpret results. We have built on an existing network of hospitals and health systems that have standardized a common computerized data platform.
Creative problem solving is part of our DNA. To demonstrate our capabilities, Prognosis created the “Cocktail Version of i2b2”, which lets you find drink recipes based on the ingredients in your liquor cabinet. Give it a try! We can load almost anything into i2b2, and we can help you find ways to creatively solve your most challenging problems.